TLIS earnings

REDWOOD CITY, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (NASDAQ:TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced it has initiated a process to explore strategic alternatives with the goal of maximizing shareholder value. While the Company has made progress developing the Talis One® system, it believes that this is a prudent path forward given current market conditions. As part of this process, the Company's Board of Directors has appointed a special committee of independent, disinterested directors to consider a

REDWOOD CITY, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (NASDAQ:TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that it will report second quarter 2023 financial results and provide a business update on Thursday, August 10, 2023, after market close. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time). The live webcast of the event may be accessed by registering online for dial-in information via the News & Events page of the investor section o

REDWOOD CITY, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (NASDAQ:TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that it will provide a business update and financial results on Thursday, May 11, 2023, after market close. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time). The live webcast of the event may be accessed by registering online for dial-in information via the News & Events page of the investor section of Talis Biomedical's w

REDWOOD CITY, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (NASDAQ:TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today reported financial results for the third quarter ended September 30, 2022. "During the third quarter, we made further progress in manufacturing the Talis One™ platform and returned to our original focus on Women's and Sexual Health, where there remains a large unmet need for infectious disease testing at the point of care. To address these significant opportunities, we are immediately directing our efforts on th

REDWOOD CITY, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (NASDAQ:TLIS), a company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today provided a business update and reported financial results for the second quarter ended June 30, 2022. In the second quarter, Talis continued to make progress on its ability to manufacture the Talis One™ system at scale. Talis successfully implemented modifications to manufacturing processes, quality controls and supply conformance resulting in improved quality and yield of cartridges and instruments. Based on evolving mar

MENLO PARK, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (NASDAQ:TLIS), a company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today reported financial results for the first quarter ended March 31, 2022. Business update Completed assessment of manufacturing processes and product design for manufacturing at scale and initiated necessary refinements.Completed first release of Sia Dx™ cloud-based software on Talis One™ System.Completed spending reduction plan to preserve cash. "Following our assessment with independent experts, we remain confident there is

MENLO PARK, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation ("TLIS"), a company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that it will report first quarter financial results on Tuesday, May 10, 2022, after market close. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time). Interested parties may access the live call via telephone by dialing 833-715-1329 for participants in the U.S. or Canada and 430-775-1933 for international callers, using conference ID 8872347

MENLO PARK, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (NASDAQ:TLIS), a company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2021. Talis has not started its phased launch of the Talis One™ COVID-19 Test System due to challenges with manufacturing. The company has engaged in a manufacturing review process to determine appropriate next steps and undertaken initiatives to align resources and preserve cash. "Since assuming the role of CE

MENLO PARK, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation ("TLIS"), a company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that it will report fourth quarter and full year 2021 financial and operational results on Tuesday, March 15, 2022, after market close. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time). Interested parties may access the live call via telephone by dialing 833-715-1329 for participants in the U.S. or Canada and 430-775-1933 for internationa

MENLO PARK, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (NASDAQ:TLIS), a company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today reported financial results and business progress for the third quarter ended September 30, 2021. "We are pleased to report meaningful progress against our previously outlined business initiatives, highlighted by the FDA's recent Emergency Use Authorization for use of the Talis One COVID-19 Test System in a variety of healthcare settings," said Kim Popovits, interim chief executive officer of Talis. "As we are launching both

Authorized for use in a variety of healthcare and congregate settings, Talis One™ enables lab-quality results without the wait to detect or rule out COVID-19 in less than 30 minutes Talis One's robust dual gene target design optimizes test sensitivity and inclusivity of variants including the highly transmissible Delta variant1 Company to provide additional details during its Q3 earnings conference call on November 15th MENLO PARK, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (NASDAQ:TLIS) today announced that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for its Talis One™ COVID-19 Test System - a nucleic acid ampl

MENLO PARK, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation ("TLIS"), a company dedicated to developing innovative molecular diagnostic tests for infectious diseases at the point-of-care, today announced that it will release financial results for the third quarter after market close on Monday, November 15, 2021. Talis will host a conference call, beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to discuss financial and operational results. Interested parties may access the live call via telephone by dialing 833-715-1329 for participants in the U.S. or Canada and 430-775-1933 for international callers, using conference ID 3618139. A live and archived webc

MENLO PARK, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (NASDAQ:TLIS), a company dedicated to developing innovative molecular diagnostic tests for infectious diseases at the point-of-care, today reported financial results and business progress for the second quarter ended June 30, 2021.   "During the second quarter, we made meaningful progress on the execution of our strategic business initiatives, including the successful completion of our point-of-care clinical validation study for the Talis One™ COVID-19 assay and subsequent EUA submission to the FDA in July," said Brian Coe, Chief Executive Officer of Talis. "As we prepare for commercial launch of this fir

MENLO PARK, Calif., July 27, 2021 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation ("TLIS"), a company dedicated to developing innovative molecular diagnostic tests for infectious diseases at the point-of-care, today announced that it will release financial results for the second quarter after market close on Tuesday, August 10, 2021. Talis will host a conference call, beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to discuss financial and operational results. Interested parties may access the live call via telephone by dialing 833-715-1329 for participants in the U.S. or Canada and 430-775-1933 for international callers, using conference ID 5966606. A live and archived webc